[PDF] Top 20 PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence

... programmed cell death-1 (PD-1), and others then acts to downmodulate T-cell effector functions when engaged with cognate ...tissues. PD-1 binds to its ligands PD-L1 ... See full document

... the current under- standing, programmed death-1 (PD-1) can combine with programmed death-ligand 1 (PD-L1) to confine T cell activity in the tumor microenvironment, and ... See full document

... of cell functions and many biological and pathological ...increasing evidence suggests that MAP4K4 also plays an important role in cancer and MAP4K4 may represent a novel actionable cancer ... See full document

... the current study, we present a pre-clinical rationale for, and clinical evidence of, potential long-term anti-tumor immunity after administration of anti-PD-1, an immune checkpoint ...Agents ... See full document

... randomized design rested on the noninferiority comparative effectiveness of 800 mg once daily continuous dosing of pazopanib relative to 50 mg once daily 4/6 weeks dosing of sunitinib. For this purpose, a noninferiority ... See full document

... Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC), and is frequently accompanied by the genetic features of von ... See full document

... Despite these challenges, researchers have begun examin- ing the novel application of VEGFR TKIs in the treatment of non-clear cell RCC and have found evidence suggestive that VEGF TKIs have ... See full document

... melanoma, PD-1 pathway inhibition is efficacious against a wide spectrum of solid and hematological malignancies includ- ing RCC, non-small cell lung cancer, bladder cancer, and Hodgkin’s ...is ... See full document

... showed evidence of Tie2 in 31 (80%) of 39 HCC samples (24/27, 89% moderately differentiated tumors; 4/6, 67% poorly differenti- ated tumors; and 1/6, 17% well differentiated ... See full document

... Several human disease states are candidates for ET A receptor antagonist pain reduction therapies. Diseases impli- cated include diabetic neuropathies, trigeminal neuralgia, crushed nerve syndrome, chronic arthritis, and ... See full document

... multiple therapeutic targets and the development of novel im- munotherapy drugs ...a PD-L1 inhibitor, has been effective against various malignancies in pre- clinical studies and clinical trials with a ... See full document

... in renal transplantation ...ovarian carcinoma [16], bladder cancer [27], and colorectal cancer ...decreased cell viability and migration and induced cell cycle arrest and apoptosis in NPC ... See full document

... lary RCC, with only marginal significance (P = 0.050). Moreover, the sample size was relative- ly small, and protein expression was not assessed. Other studies reported no apparent correlation between VEGF expression ... See full document

... Abstract: Despite improved methods of cancer detection and disease management over the last few decades, cancer remains a major public health problem in many societies. Conventional therapies, such as chemotherapy, ... See full document

... clear cell variety of ...grade 1 tumours, 65% in case of grade 2 tumours and 46% in case of grades III-IV ...clear cell type of ...type 1 tumours generally have a better prognosis than the ... See full document

... Regarding tumor site, detectable levels of ctDNA was found in more than 75% of patients with metastatic cancer of pancreas, bladder, colon, breast, liver, stomach, and in less than 50% of patients with metastatic RCC, ... See full document

... An alternate DC vaccine has been tested in combination with docetaxel/prednisolone in patients with CRPC. Importantly, the addition of immunotherapy in the form of DC therapy did not seem to increase toxicity. All of the ... See full document

... of PD-L1 expression. Cases were grouped as follows: 1. PD-L1 negative, no microvascular tumor invasion and low Fuhrman nuclear grade; ...iables: PD-L1 expression, microvascular tumor invasion ... See full document

... Mast Cells (MC) are tissue-resident, bone-marrow derived, granular sentinel cells. They enter circulation from the bone marrow as committed Mast Cell Progenitors (MCP) and undergo terminal differentiation in ... See full document

... 4. Lee WK, Byun SS, Kim HH, Rha KH, Hwang TK, Sung GT, Lee W, Lim JS, Jeong YB, Kwon TG. Characteristics and prognosis of chromophobe non-metastatic renal cell carcinoma: a multicenter study. Int J ... See full document